Si terapia #EMPIRICA con #Vancomicina y Micro🧫🔬 informa #Saureus SENSIBLE a meticilina 🍇❌🛡️CAMBIA a betalactamico {cefazolina, cloxa)🔴🔄💉desde 2011 (Schweizer M.#BMCInfectDis) sabemos q MORTALIDAD MAYOR si seguimos con #Vancomicina🔴☠️📈
🔗🆓https://t.co/0Wsg7rAnQG
⏳ ¡Últimos semanas para apuntarte al curso de verano del PRAN! #CV2026
👉 “Resistencia a antibióticos y #OneHealth”
📅 1–3 julio
📍 El Escorial
🎓 Para estudiantes y profesionales sanitarios
✅ Becas e inscripciones: https://t.co/A3jsMINLsc
#ResistenciaAntibióticos#AMR
Asociar una cefalosporina Anti-SAMR (#ceftarolina o #Ceftobiprole) a #DAPTOMICINA en bacteriemia por #SaureusMR🩸🍇🛡️? En @CIDJournal cohorte retrospectiva 465 pacientes donde esta combinación🍸tuvo MENOR mortalidad 📉☠️que otros regímenes antibióticos
🔗🆓https://t.co/xsBJjJ5NYe
🆕💥🟢Retrospective observational study
Anti-MRSA Cephalosporins + Daptomycin as Initial Therapy for MRSA Bacteremia: Does a “Hit Hard and Fast” Strategy Improve Outcomes?
#idxposts#DOOR https://t.co/tmxkAH35QV
🆕💥🟢Optimizing Pneumocystis jirovecii Prophylaxis in Immunocompromised Patients: Defining the Clinical Role of Atovaquone
After atovaquone, 67 patients transitioned to an alternative, most commonly cotrimoxazole (56/67, 84%). There were no breakthrough PJP cases.
https://t.co/CdH3oR5jkg
🎓Actividad formativa @GeSIDA_SEIMC, webinar "Seminario Cáncer y VIH: Panorama actual y retos clínicos"
📅 hasta el 15 de diciembre de 2026
📍Campus @SEIMC_
📚📝Programa/Inscripción👇
https://t.co/OCwihn5lc7
Another step toward individualized dalbavancin dosing for complicated MRSA infections
🆕💥🔴Multicenter population PK study
Standard labeled regimens achieved 4-week PTA in only 50–60% of obese patients,with the lowest attainment observed among those with eGFR ≥120 mL/min. #idxposts
https://t.co/nNhIFx8cRe
Today's Paper of the Day is:
Invasive Candidiasis in Critically Ill Patients: Fundamental Concepts and Future Directions
https://t.co/JKgcYjlUQ5
Join us to read 1 paper per day and stay up-to-date as we cover the spectrum of critical care across 2026
🆕💥 🔴 Case Report
Emergence of Dalbavancin Non-Susceptible Methicillin-Resistant Staphylococcus epidermidis in a Patient Treated With Dalbavancin prolonged therapy despite adequate systemic exposure.
🔺walK and rpoB, vraG mutations differentially associated to reduced susceptibility
🔺Dalbavancin exhibited high synergy interaction with fosfomycin against MRSE in vitro#idxposts
https://t.co/oSDGE7JKM4
Uno de los grandes debates del #CongresoSEIMC2026 ha sido la urgencia de la especialidad MIR en #EnfermedadesInfecciosas. A raíz de esto, @elconfidencial ha entrevistado a una de las ponentes, la Dra. Elisa Ruiz, cuyo caso personal ilustra perfectamente la problemática👇🧵